Epidemiology of *Candida albicans* and non-*C. albicans* of neonatal candidemia at a tertiary care hospital in western China

Jinjian Fu 1†, Yanling Ding 1†, Ba Wei 2†, Lin Wang 3†, Shaolin Xu 1, Peixu Qin 1, Lihua Wei 4* and Lijun Jiang 4*

Abstract

**Background:** Although the majority of *Candida* infections occur in the developing world, candidemia epidemiology is poorly understood in these countries. The aim of this study was to investigate the epidemiology of non-*Candida albicans* (non-C. albicans) candidemia among neonates at Liuzhou Maternity and Child Healthcare Hospital in China.

**Methods:** A retrospective review of all positive blood culture about *Candida* species in neonatal intensive care unit was conducted between January 2012 and November 2015. Information about demographics, risk factors and outcome of candidemia were collected. Univariate and multivariate logistic regression models were used to identify the risk factors associated with the development of non-*C. albicans* candidemia.

**Results:** The prevalence of candidemia in infants was 1.4%. Non-*C. albicans* was responsible for 56.5% of neonatal candidemia. The predisposing factors for development of non-*C. albicans* candidemia among infants included mechanical ventilation (odds ratio (OR), 95% confidence interval (95%CI) = 3.13, 1.07–9.14; *P* = 0.037) and use of assisted reproductive technology (OR, 95%CI = 4.52, 1.39–14.77; *P* = 0.012). The overall mortality rate of candidemia was 8.7% and non-*C. albicans* attributed to 83.3% of all mortalities.

**Conclusions:** Non-*C. albicans* species are the major cause of candidemia in local neonatal group. The study highlights the urgent needs to evaluate the possibility of development of non-*C. albicans* candidemia in neonates exposed to these risk factors and much emphasis must be laid on the early implementation of medical intervention to reduce the incidences of candidemia in neonates.

**Keywords:** Infants, Candidemia, Non-*C. albicans*, Assisted reproductive technology

**Background**

*Candida* species are the third most common pathogens that attributed to neonatal bloodstream infections and are associated with 20–34% mortality [1, 2]. Although *Candida albicans* has long been the most common cause of candidemia infections obtained from neonatal intensive care units (NICUs) [3, 4]. *Non-C. albicans* species such as *Candida glabrata* (*C. glabrata*), *Candida tropicalis* (*C. tropicalis*), *Candida parapsilosis* (*C. parapsilosis*) and *Candida krusei* (*C. krusei*) have emerged as the second or even the predominant pathogens that caused neonatal candidemia in some local hospitals [5].

Infants are more vulnerable to develop candidemia due to their critical underlying conditions, immature immune system, and invasive operations [6, 7]. The predisposing factors contributing to the current increase of neonatal candidemia included prematurity, very low birth weight, aggressive broad-spectrum antibiotics, prolonged hospitalization, invasive operations such as central venous catheters, intubation and total parenteral nutrition [8–12].

As the *Candida* species formed the biofilms on the surface of indwelling medical appliances, their high virulence, the documented horizontal nosocomial transmission, vertically from mother to neonate, and their developmental of resistance to azole antifungal agents [8, 9, 13], the neonatal candidemia has presented a challenge to pediatricians.
Although several studies had reported the epidemiology of Candida infections in China, they mainly focused on adults, invasive Candida infections or conducted among special groups [14–17]. The investigation about Candida albicans (Calbicans) compared to non-Calbicans candidemia in neonatal groups are limited in China [18]. It is important to know local information about candidemia infections in NICUs as the Candida infections at local levels could provide pediatricians the full information to implement early medical practice to diagnosis and treat these high-risk groups. This retrospective study aimed to investigate the epidemiology of candidemia in neonatal groups at a single center in western China.

Methods
Study design and data collection
This retrospective study was conducted between January 2012 and November 2015, in NICU of Liuzhou Maternity and Child Healthcare Hospital. The medical charts for 5075 admissions during the 4-year period were reviewed. Infants with positive blood culture results of Candida species were included as candidemia. Collected demographics on previously identified risk included necrotizing enterocolitis, neurodevelopmental impairment, maternal underlying diseases (such as preeclampsia, gestational diabetes, pregnancy-induced hypertension, cholestasis, hyperthyroidism, hypothyroidism, etc.), respiratory distress, vaginal birth, fetal membrane rupture, neonatal congenital diseases (such as congenital heart disease, Glucose-6-Phosphate Dehydrogenase deficiency, thalassemia, etc.), abdominal surgery, mechanical ventilation, central venous catheter, intubation, pulmonary active substance use, steroids use, antacid use, total parenteral nutrition, hospitalization duration, 3rd cephalosporins use, carbapenem use, vancomycin use, multiple antibiotic (≥3 classes) use, antibiotic therapeutic duration (including the administration of antibiotics prior to the occurrence of candidemia and the prophylaxis antibiotic use during hospitalization), use of prophylaxis antifungal agent (fluconazole), and antifungal therapeutic duration. The collection data from medical chart was permitted by the Institutional Review Board.

Microbiologic methods
Blood samples were cultured in the BacT/AlerT 3D system (Biomérieux). Chromo Agar medium was used for Candida species identification (Biomérieux) and API 20C AuX (Biomérieux) was used for confirmation.

Statistical analysis
SPSS version 20.0 statistical software (SPSS Inc., Chicago, IL, USA) was used. Potential risk factors associated with increased candidemia risk were identified using univariate logistic regression analysis. Variables with 2-tailed P < 0.05 were included in the multivariate logistic regression model to evaluate the odds ratios (ORs) and 95% confidence intervals (CIs) to calculate the strength of any association. A P-value less than 0.05 was considered indicative of statistical significance.

Results
The distribution of Candida species and incidence of candidemia
There were 5075 admissions of neonates (aged <28 days) in the NICU, 69 infants had Candida bloodstream infections during the 4-year study period. The incidence of candidemia was 1.4%. Calbicans was the leading causative pathogen of candidemia and it was isolated in 43.5% of the patients. Non-Calbicans was responsible for 56.5% of neonatal candidemia. The distribution of non-Calbicans species was C.glabrata for 33.3%, C.tropicalis for 20.3%, C.parapsilosis for 1.4% and C.kefyr for 1.4%.

Risk factors associated with candidemia due to non-C.albicans
Infant demographics and risk factors for candidemia are shown in Table 1. There was no difference between Calbicans and non-Calbicans in terms of the gestational age (31.7 vs 31.5 weeks, P = 0.765), birth weight (1670.0 g vs 1417.6 g, P = 0.128), or male gender (16.7% vs 30.8%, P = 0.150).

In the univariate logistic regression model, mechanical ventilation was significantly more common in neonates with candidemia caused by non-Calbicans (74.4% vs 46.7%, P = 0.021). The antibiotic therapeutic duration was longer in the non-Calbicans group compared to Calbicans group (38.0 vs 28.1 days, P = 0.033). Among infants with candidemia, 48.7% were conceived using assisted reproductive technology, compared with 16.7% in Calbicans group (P = 0.008).

Based on step-wise multivariate logistic regression analysis, infants with non-Calbicans candidemia infections were more likely to undergo mechanical ventilation (OR, 95%CI = 3.13, 1.07–9.14, P = 0.037). Infants who were conceived using assisted reproductive technology were more likely to develop non-Calbicans candidemia (OR, 95%CI = 4.52, 1.39–14.77, P = 0.012) (Table 2).

Outcome
The overall mortality among affected infants was 5.8%. Calbicans and non-Calbicans were associated with a mortality rate of 3.3%, 12.8%, respectively. There was no significance between the two groups (P = 0.197).
Discussion

*Candida* species have emerged as important pathogens which are associated with significant morbidity and mortality in neonates [1, 10]. In the past two decades, there have been several cohort studies indicating that the cause of *Candida* bloodstream infection has shifted from *C.albicans* to *non-C.albicans* [19–21]. Widespread use of azole antifungal agents, especially fluconazole, was one of the reasons contributing to the increased isolation rate of *non-C.albicans* and the decreased isolation rate of *Calbicans* [22, 23]. Many studies from western countries showed that *C.albicans* was the predominant *Candida* species isolated from candidemia, followed by *C.parapsilosis* among infants [3, 22]. It was reported that *C.parapsilosis* attributed to one-fifth of all cases of candidemia in neonates [24]. Our study revealed that *C.parapsilosis* attributed to only 1.4% of all cases of neonatal candidemia. In our study, we observed a changing pattern of neonatal candidemia among infant patients. The most frequent *Candida* species isolated from the bloodstream was *C.albicans* (43.5%). The most common *non-C.albicans* species was *C.glabrata* (33.3%), followed

### Table 1 Clinical characteristics of neonates between *Calbicans* and *non-Calbicans*

| Variable                  | *Calbicans* mean (95% CI) or n (%) | *non-Calbicans* mean (95% CI) or n (%) | *P* value | odds ratio (OR) (95% CI) |
|---------------------------|-----------------------------------|----------------------------------------|-----------|--------------------------|
| Demographics              |                                    |                                        |           |                          |
| gestational age (wks)     | 31.7 (27.6, 35.8)                 | 31.5 (27.7, 36.3)                     | 0.765     |                          |
| birth weight (g)          | 1670.0 (962.1, 2377.9)            | 1417.6 (777.1, 2058.1)                | 0.128     |                          |
| male gender, n (%)        | 22 (73.3)                         | 22 (56.4)                             | 0.150     | 0.47 (0.17–1.32)         |
| admission age             | 2.1 (2.0, 6.2)                    | 1.1 (0.6, 1.6)                        | 0.138     |                          |
| Risk factors              |                                    |                                        |           |                          |
| necrotizing enterocolitis | 5 (16.7)                          | 12 (30.8)                             | 0.183     | 2.22 (0.69–7.21)         |
| neurodevelopmental impairment | 7 (23.3)                     | 8 (20.5)                              | 0.778     | 0.85 (0.27–2.68)         |
| maternal underlying diseases | 12 (40.0)                    | 18 (46.2)                             | 0.609     | 1.29 (0.50–3.36)         |
| assisted reproductive technology | 5 (16.7)                  | 19 (48.7)                             | 0.008     | 4.75 (1.51–14.96)        |
| vaginal birth             | 19 (63.3)                         | 23 (59.0)                             | 0.713     | 1.20 (0.45–3.20)         |
| fetal membrane rupture (h) | 164 (28.4, 61.2)                 | 266 (36.0, 89.2)                      | 0.459     |                          |
| congenital diseases       | 13 (43.3)                         | 24 (61.5)                             | 0.135     | 2.09 (0.80–5.51)         |
| abdominal surgery         | 4 (13.3)                          | 6 (15.4)                              | 0.811     | 1.18 (0.30–4.63)         |
| mechanical ventilation    | 14 (46.7)                         | 29 (74.4)                             | 0.021     | 3.31 (1.20–9.15)         |
| central venous catheter   | 14 (46.7)                         | 27 (69.2)                             | 0.061     | 2.57 (0.96–6.91)         |
| intubation                | 10 (33.3)                         | 21 (53.8)                             | 0.092     | 2.33 (0.87–6.26)         |
| pulmonary active substance use | 7 (23.3)                     | 9 (23.1)                              | 0.980     | 0.99 (0.32–3.04)         |
| steroids use              | 6 (20.0)                          | 9 (23.1)                              | 0.759     | 1.20 (0.38–3.84)         |
| antacid use               | 3 (10.3)                          | 8 (21.1)                              | 0.250     | 2.50 (0.56–9.63)         |
| total parenteral nutrition | 23 (76.7)                         | 36 (92.3)                             | 0.080     | 3.65 (0.86–15.57)        |
| hospitalization duration (d) | 43.8 (19.1, 78.5)               | 49.1 (26.6, 71.6)                     | 0.367     |                          |
| 3rd cephalosporins use    | 16 (55.2)                         | 23 (59.0)                             | 0.754     | 1.17 (0.44–3.08)         |
| carbapenems use           | 21 (70.0)                         | 30 (76.9)                             | 0.517     | 1.43 (0.49–4.20)         |
| vancomycin use            | 4 (13.3)                          | 6 (15.4)                              | 0.811     | 1.18 (0.30–4.63)         |
| multiple antibiotic use   | 19 (63.3)                         | 18 (46.2)                             | 0.158     | 0.50 (0.19–1.31)         |
| antibiotic therapeutic duration (d) | 28.1 (10.0, 46.2)      | 38.0 (19.3, 56.7)                     | 0.033     |                          |
| prophylaxis antifungal therapy | 19 (63.3)                    | 32 (82.1)                             | 0.084     | 2.65 (0.88–7.99)         |
| antifungal therapeutic duration (d) | 7.9 (2.3, 13.5)       | 8.8 (2.3, 15.3)                        | 0.535     |                          |
| Outcome                   |                                    |                                        |           |                          |
| death                     | 1 (3.3)                           | 5 (12.8)                              | 0.197     | 4.27 (0.47–38.62)        |

### Table 2 Multivariate analysis for *Calbicans* and *non-Calbicans*

| Risk factor                | Odds ratio | 95% CI | *P* value |
|----------------------------|------------|--------|-----------|
| assisted reproductive technology | 4.52 | 1.39–14.77 | 0.012 |
| mechanical ventilation     | 3.13       | 1.07–9.14 | 0.037 |
by *C. tropicalis* (20.3%). The *non*-*C. albicans* together accounted for more than 55% of all candidemia in our center. This species distribution pattern varied from western countries but was consistent with studies conducted in Australia and in 11 NICUs in China [21, 25]. It was reported that the difference of prevalence of candidemia due to a specific *Candida* species may vary by geographic region [15], and some researches recommended that the study should focus at the local level rather than at the worldwide scale [26]. One of the outbreak of candidemia caused by *C. parapsilosis* reported from a Chinese hospital revealed that all strains were susceptible to fluconazole [27]. Fluconazole has been recommended as the best alternative antifungal drug for both of prophylaxis and primary treatment for patients with candidemia due to its efficacy and safety [28, 29]. In China, *C. parapsilosis* isolated from sterile body fluids have rarely been reported to be resistant to fluconazole [30, 31]. A prospective cohort study from a teaching hospital conducted between 2006 and 2011 reported that all 25 *C. parapsilosis* strains tested were susceptible to fluconazole [30]. The 2010 National China Hospital Invasive Fungal Surveillance Net (CHIFNET) program found that only 1.4% of *C. parapsilosis* strains were resistant to fluconazole [31]. Based on those studies, we can state with certainty that *C. parapsilosis* specie isolated from blood stream is still highly susceptible to fluconazole in Chinese region and the use of fluconazole for prophylaxis in our hospital can be effective.

Many investigations have confirmed that use of broad-spectrum antibiotics and prolonged antibiotic therapeutic duration were the most common risk factors associated with neonatal candidemia [32]. A previous study showed that prolonged use of 3rd generation cephalosporin was associated with neonatal candidemia due to *C. parapsilosis* in infants [33]. Previous studies also suggested that prolonged antibiotic therapeutic duration predisposed to *C. glabrata* was attributed to candidemia [34, 35]. Our observation was in agreement with the general view that prolonged antibiotic use was associated with an increase of *non*-*C. albicans* candidemia in patients. It was reported that universal exposure to antibacterial drugs would suppress the bacterial flora and facilitate *Candida* colonization, which may increase the potential risk of development of candidemia [32]. These findings highlight the importance of evaluating the antibacterial burden in infected neonates.

In the multivariate logistic regression models, we found that mechanical ventilation affected the risk of candidemia infection with *non*-*C. albicans* isolates. It is well known that mechanical ventilation would play an important role in the pathogenesis of invasive candidiasis because of abrading the respiratory mucosa, providing *Candida* species for a portal of entry into the bloodstream [32]. Once *Candida* species adheres to the surface of invasive medical devices, it can form a biofilm thus protecting itself from immune responses and antifungal therapy.

Additionally, our analysis identified that use of assisted reproductive technology (ART) such as in vitro fertilization-assisted pregnancy would serve as an independent risk factor for development of *non*-*C. albicans* candidemia in newborns (OR, 95% CI = 4.52, 1.39–14.77, *P* = 0.012). This association may be partly due to the high proportion infection caused by *C. glabrata* among the neonates whom were the production of ART. In the *non*-*C. albicans* candidemia group, 73.7% (14/19) of neonates were conceived using ART. Globally, few studies have verified the association of ART and the outcome of neonatal candidemia. Most of the previous literature focused on the *Candida* species was associated with chorioamnionitis in in vitro fertilization (IVF) pregnancy [36]. It was reported that some types of uterine manipulation, such as IVF, may introduce the fungus at the time of embryo transfer [37]. Although *C. glabrata* showed a reduced virulence and absence of pathognomonic lesions compared with *C. albicans*, there was strong documented evidence of association between chorioamnionitis caused by *C. glabrata* and the use of ART, and the high lethality and morbidity in such group [38]. One of the studies showed that in 72% of cases of *C. glabrata* chorioamnionitis, conception was through ART [39]. These results raised the concern of the need for *Candida* species screening prior to IVF initialization. Although we failed to find out the data of culture results before embryo transfer, 73.9% of the infected neonates had received prophylaxis antifungal agents (fluconazole). Among the patients who were conceived using ART, 91.7% cases were administered fluconazole for prophylactic use. This may partly explain why the mortality rate was lower (overall mortality rate was 8.7%) that previous reports (24–30% in neonatal candidemia) [32].

The main limitation of our study was the retrospective design and the small sample size, which may compromise the statistical power. Additionally, we cannot collect the data of maternal yeasts colonization before and after delivery, which may not provide the enough information for evaluation of the vertical transmission and the association about maternal yeasts colonization and the subsequence of development of neonatal candidemia. Nevertheless, our data revealed that prolonged antibiotic therapeutic duration, mechanical ventilation and use of assisted reproductive technology were all the independent risk
factors for the development of neonatal non-C. albicans candidemia.

Conclusions
Non-C. albicans species are the major cause of candidemia in local neonatal group. The study highlights the urgent need to evaluate the possibility of development of non-C. albicans candidemia in neonates exposed to these risk factors and much emphasis must be laid on the early implementation of medical intervention to reduce the incidences of candidemia in neonates.

Abbreviations
95%CI: 95% confidence intervals; ART: Assisted reproductive technology; C.albicans: Candida albicans; C.glabrata: Candida glabrata; C.krusei: Candida krusei; C.parapsilosis: Candida parapsilosis; C.tropicalis: Candida tropicalis; CHIFNET: China Hospital Invasive Fungal Surveillance Net; IVF: in vitro fertilization; NICUs: Neonatal intensive care units; non-C. albicans: non-Candida albicans; ORs: Odds ratios

Acknowledgements
Not applicable.

Funding
None.

Availability of data and materials
The datasets generated and/or analyzed during the current study are not publicly available due to the confidentiality permission with the Institutional Review Board but are available from the corresponding author on reasonable request.

Authors’ contributions
YD and LJ designed the study and drafted an outline. JF, YD, BW, LW, SX, PQ, LW and LJ participated in data analysis, JF drafted the manuscript and revised it critically for important intellectual content. All of authors approved the final content off this manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
This study was approved by the Institutional Review Board of Liuzhou Maternity and Child Healthcare Hospital.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1. Department of Laboratory, Liuzhou Maternity and Child Healthcare Hospital, Liuzhou, China. 2. Department of Neonatology, Liuzhou Maternity and Child Healthcare Hospital, Liuzhou, China. 3. Department of Science and Education, Liuzhou Maternity and Child Healthcare Hospital, Liuzhou, China. 4. Department of Laboratory, Liuzhou Worker’s Hospital, No 1 Liushi Rd, Liuzhou 545005, China.

Received: 10 October 2016 Accepted: 26 April 2017

Published online: 06 May 2017

References
1. Benjamin DK Jr, Stoll BJ, Fanaroff AA, McDonald SA, et al. National Institute of Child Health and Human Development neonatal research network. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics. 2006;117:84–92.
2. Shetty SS, Harrison LH, Hajeh RA, Taylor T, et al. Determining risk factors for candidemia among newborn infants from population-based surveillance: Baltimore, Maryland, 1998-2000. Pediatr Infect Dis J. 2005;24:601–4.
3. Ozer C, Nairn AG, Heath PT, Sharland M, et al. The epidemiology of neonatal and pediatric candidemia in England and Wales, 2000-2009. Pediatr Infect Dis J. 2013;32:23–6.
4. Steinbach WJ, Rolildes E, Berman D, Hoffman JA, et al. Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates. Pediatr Infect Dis J. 2012;31:1252–7.
5. Trofa D, Gàsca A, Nosanchuk JD. Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev. 2008;21:606–25.
6. Filoti J, Spironolou K, Pantelidis CP, Rolildes E. Invasive candidiasis in pediatric intensive care patients: epidemiology, risk factors, management, and outcome. Intensive Care Med. 2007;33:1272–83.
7. Carey AJ, Saiman L, Pollin RA. Hospital-acquired infectious in the NICU: epidemiology for the new millennium. Clin Perinatol. 2008;35:223–49.
8. Sighi S, Deep A. Invasive candidiasis in pediatric intensive care units. Indian J Pediatr. 2009;76:1033–44.
9. Rolildes E. Invasive candidiasis in neonates and children. Early Hum Dev. 2011;87:575–6.
10. Benjamin DK Jr, Stoll BJ, Gantz MG, Walsh MC, et al. Neonatal candidiasis: epidemiology, risk factors, and clinical judgment. Pediatrics. 2010;126:e665–73.
11. Rodriguez D, Almirante B, Park BJ, Cuerva-Estrella M, et al. Candidemia in neonatal intensive care units: Barcelona, Spain. Pediatr Infect Dis J. 2006;25:224–9.
12. Fridkin SK, Kaufman D, Edwards JR, Shetty S, et al. Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995-2004. Pediatrics. 2006;117:1680–7.
13. Tumbarello M, Postoraro B, Trecarichi EM, Fion B, et al. Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia. J Clin Microbiol. 2007;45:1843–50.
14. Li C, Wang H, Yin M, Han H, et al. The differences in the epidemiology and predictors of death between candidemia acquired in intensive care units and other hospital settings. Intern Med. 2015;54:3009–16.
15. Zhang XB, Yu SJ, Yu JX, Gong YL, et al. Retrospective analysis of epidemiology and prognostic factors for candidemia at a hospital in China, 2000-2009. Jpn J Infect Dis. 2012;65:510–5.
16. Wu Z, Liu Y, Feng X, Liu Y, et al. Candidemia incidence rates, type of species, and risk factors at a tertiary care academic hospital in China. Int J Infect Dis. 2014;22:4–8.
17. Ding X, Yan D, Sun W, Zeng Z, et al. Epidemiology and risk factors for nosocomial Non-Candida albicans candidemia in adult patients at a tertiary care hospitals in North China. Med Mycol. 2015;53:684–90.
18. Hua S, Huang J, Wu Z, Feng Z. A comparison study between Candida parapsilosis sepsis and Candida albicans sepsis in preterm infants. Turk J Pediatr. 2012;54:502–8.
19. Dzierzanowska-Fangrat K, Romanowska E, Gryniowicz-Kwiatkowska O, Mogdai M, et al. Candidemia in a polish tertiary paediatric hospital, 2000 to 2010. Mycoses. 2014;57:105–9.
20. Velasco BR. A prospective cohort study evaluating the prognostic impact of clinical characteristics and comorbid conditions of hospitalized adult and pediatric cancer patients with candidemia. Eur J Clin Microbiol Infect Dis. 2008;27:1071–8.
21. Blyth CC, Chen SC, Slavin MA, Serena C, et al. Australian Candidemia Study. Not just little adults: candidemia epidemiology, molecular characterization, and anti-fungal susceptibility in neonatal and pediatric patients. Pediatrics. 2009;123:1360–8.
22. Sendid B, Cotteau A, Francois N, D’Haveloose A, et al. Candidemia and antifungal therapy in a French university hospital: rough trends over a decade and possible links. BMC Infect Dis. 2006;6:80–8.
23. Trick WE, Fridkin SK, Edwards JR, Hajeh RA, et al. National Nosocomial Infections Surveillance System Hospitals. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis. 2003;36:627–30.
24. Ozer C, Vergnano S, Naidoo R, Anthony M, et al. Neonatal invasive fungal infection in England 2004-2010. Clin Microbiol Infect. 2014;20:36–41.
25. Xia H, Wu H, Xia S, Zhu X, et al. Invasive candidiasis in preterm neonates in China: a retrospective study from 11 NICUS during 2009-2011. Pediatr Infect Dis J. 2014;33:106–9.
26. Mikulsha M, Bassetti M, Ratto S, Viscoli C. Invasive candidiasis in non-hematological patients. Mediterr J Hematol Infect Dis. 2011;3:e2011007.

27. He W, Zhang L, Kudinha T, Kong F, et al. Investigation of an unrecognized large-scale outbreak of Candida parapsilosis Sensu stricto fungaemia in a tertiary-care hospital in China. Sci Rep. 2016;6:27099.

28. Pinhati HM, Casalati LA, Souza AG, Siqueira RA, et al. Outbreak of candidemia caused by fluconazole resistant Candida parapsilosis strains in an intensive care unit. BMC Infect Dis. 2016;16(1):433.

29. Pappas PG, Kauffman CA, Andes D, Benjamin DK, et al. Clinical practice guidelines for the management of candidiasis. 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503–35.

30. Li F, Wu L, Cao B, Zhang Y, et al. Surveillance of the prevalence, antibiotic susceptibility, and genotypic characterization of invasive candidiasis in a teaching hospital in China between 2006 to 2011. BMC Infect Dis. 2013;13:353.

31. He W, Xiao M, Chen SC-A, Kong F, et al. In vitro susceptibilities of yeast species to Fluconazole and Voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance net (CHIF-NET) study. J Clin Microbiol. 2012;50(12):3952–9.

32. Kelly MS, Benjamin DK Jr, Smith PB. The epidemiology and diagnosis of invasive candidiasis among premature infants. Clin Perinatol. 2015;42:105–17.

33. Benjamin DK Jr, Ross K, Mckinney RE Jr, Benjamin DK, et al. When to suspect fungal infection in neonates: a clinical comparison of Candida albicans and Candida parapsilosis fungemia with coagulase-negative staphylococcal bacteremia. Pediatrics. 2000;106:712–8.

34. Chow JK, Golan Y, Ruthazer R, Karchmer AW, et al. Risk factors for albicans and non-albicans candidemia in the intensive care unit. Crit Care Med. 2008;36:1993–8.

35. Lin MY, Carmeli Y, Zumsteg J, Flores EL, et al. Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study. Antimicrob Agents Chemother. 2005;49:4555–60.

36. Ganer Herman H, MevorachZussman N, KrajdenHaratz K, Bar J, et al. Candida glabratachorioamnionitis following in vitro fertilization: review of the literature. Gynecol Obstet Invest. 2015;80:145–7.

37. Asemota OA, Nyirjesy P, Fox R, Sobel JD. Candida glabrata complicating in vitro pregnancy: successful management of subsequent pregnancy. Fertil Steril. 2011;95:803, e1-2.

38. Tan SQ, Ng OT, Khong CC. Candida glabrata associated with chorioamnionitis in an IVF twin pregnancy: should we deliver? J Obstet Gynaecol Res. 2015;41:962–6.

39. Alfei A, Rizzo A, Cavanna C, Lallitto F, et al. Candida Glabrata and pre-term premature rupture of membrane complicating in vitro pregnancy: case report and confirmation of mother to neonate transmission. Arch Gynecol Obstet. 2014;290:211–4.